Amplification of AML1 in acute lymphoblastic leukemia is associated with a poor outcome.
Robinson
H M
HM
Broadfield
Z J
ZJ
Cheung
K L
KL
Harewood
L
L
Harris
R L
RL
Jalali
G R
GR
Martineau
M
M
Moorman
A V
AV
Taylor
K E
KE
Richards
S
S
Mitchell
C
C
Harrison
C J
CJ
D002648:Child; D002675:Child, Preschool; D050676:Core Binding Factor Alpha 2 Subunit; D004268:DNA-Binding Proteins / Q000235:genetics*; D018572:Disease-Free Survival; D005784:Gene Amplification; D006801:Humans; D016130:Immunophenotyping; D009363:Neoplasm Proteins / Q000235:genetics; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics* / Q000401:mortality; D011379:Prognosis; D011518:Proto-Oncogene Proteins; D013997:Time Factors; D014157:Transcription Factors / Q000235:genetics*; D016896:Treatment Outcome
D050676:Core Binding Factor Alpha 2 Subunit; D004268:DNA-Binding Proteins; D009363:Neoplasm Proteins; D011518:Proto-Oncogene Proteins; C493728:RUNX1 protein, human; D014157:Transcription Factors